PPARα: its role in the human metabolic syndrome

Bibliography

• Okrainec K, Banerjee DK, Eisenberg MJ: Coronary artery disease in the developing world. Am. Heart J. 148, 7–15 (2004).
   Google Scholar
• Epidemiological review suggesting that the developing world is currently experiencing an epidemic of coronary artery disease (CAD) and, if unchecked, CAD-associated morbidity and mortality rates are expected to continue to rise for the foreseeable future.
   Google Scholar
• American Heart Association: Heart disease and stroke statistics – 2005 update; Dallas, TX, USA. American Heart Association (2005).
   Google Scholar
• Rashid MN, Fuentes F, Touchon RC, Wehner PS: Obesity and the risk for cardiovascular disease. Prev. Cardiol. 6, 42–47 (2003).
   Google Scholar
• Review further emphasizes an association between obesity and cardiovascular disease.
   Google Scholar
• Scaglione R, Argano C, Di Chiara T, Licata G: Obesity and cardiovascular risk: the new public health problem of worldwide proportions. Expert. Rev. Cardiovasc. Ther. 2, 203–212 (2004).
   Google Scholar
• Provides additional evidence to support the concept that obesity is an independent risk factor for CAD.
   Google Scholar
• Resnick HE, Howard BV: Diabetes and cardiovascular disease. Annu. Rev. Med. 53, 245–267 (2002).
   Google Scholar
• Excellent review covering a range of topics related to epidemiology of diabetes and cardiovascular disease.
   Google Scholar
• Sobel BE, Schneider DJ: Cardiovascular complications in diabetes mellitus. Curr. Opin. Pharmacol. 5, 143–148 (2005).
   Google Scholar
• Zimmet P, Alberti KGMM, Shaw J: Global and societal implications of the diabetes epidemic. Nature 414, 782–787 (2001).
   Google Scholar
• Represents a fairly comprehensive review on the global diabetic epidemic, with special emphasis on socio-economic implications.
   Google Scholar
• Bonow RO, Gheorghiade M: The diabetes epidemic: a national and global crisis. Am. J. Med. 116(Suppl. 5A), S2–S10 (2004).
   Google Scholar
• Engelgau MM, Geiss LS, Saaddine JB et al.: The evolving diabetes burden in the United States. Ann. Intern. Med. 140, 945–950 (2004).
   Google Scholar
• Morrill AC, Chinn CD: The obesity epidemic in the United States. J. Public Health Policy 25, 353–366 (2004).
   Google Scholar
• Addresses the issue of the obesity epidemic in both adults and children in the USA. It also provides evidence implicating physical inactivity and increasing consumption of carbohydrate intake, especially in the form of soft drinks and other foods high in ‘highfructose corn syrup’, as the two main contributors to obesity.
   Google Scholar
• Haslam DW, James WP: Obesity. Lancet 366, 1197–1209 (2005).
   Google Scholar
• Prentice AM: The emerging epidemic of obesity in developing countries. Int. J. Epidemiol. 35, 93–99 (2006).
   Google Scholar
• Lillioja S, Mott DM, Spraul M et al.: Insulin resistance and insulin secretory dysfunstion as precursors of non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 1988–1992 (1993).
   Google Scholar
• This original paper provides evidence that insulin resistance is a major risk factor for the development of Type 2 diabetes.
   Google Scholar
• Goldstein BL: Insulin resistance: from benign to Type 2 diabetes mellitus. Rev. Cardiovasc. Med. 4(Suppl. 6), S3–S10 (2003).
   Google Scholar
• DeFronzo RA: Pathogenesis of Type 2 diabetes mellitus. Med. Clin. North Am. 88, 787–835 (2004).
   Google Scholar
• Kahn BB, Flier JS: Obesity and insulin resistance. J. Clin. Invest. 106, 473–481 (2000).
   Google Scholar
• Article eloquently summarizes the association between obesity and Type 2 diabetes. The authors have also raised the possibility that insulin resistance and hyperinsulinemia, in addition to being caused by obesity, may promote the development of obesity.
   Google Scholar
• Lazar MA: How obesity causes diabetes: not a tall tale. Science 307, 373–375 (2005).
   Google Scholar
• Despres J-P, Lamarche B, Mauriege P et al: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334, 952–957 (1996).
   Google Scholar
• Provides evidence that hyperinsulinemia is an independent risk factor for CAD in men.
   Google Scholar
• Pyorala M, Miettinen H, Laako M, Pyorala K: Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 98, 398–404 (1998).
   Google Scholar
• Miegs JB: Epidemiology of the insulin resistance syndrome. Curr. Diab. Rep. 3, 73–79 (2003).
   Google Scholar
• Reaven G: Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu. Rev. Med. 44, 121–131 (1993).
   Google Scholar
• Summarizes the role of insulin resistance in the pathophysiology of metabolic syndrome and its relevance to the etiology and clinical course of patients with Type 2 diabetes, hypertension and CAD.
   Google Scholar
• Leslie BR: Metabolic syndrome: historical perspective. Am. J. Med. Sci. 330, 264–268 (2005).
   Google Scholar
• Brief chronology of historical events that led to the development of modern concept of the metabolic syndrome.
   Google Scholar
• Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289–2304 (2005).
   Google Scholar
• Sarafidis PA, Nilsson PM: The metabolic syndrome: a glance at its history. J. Hypertens. 24, 621–626 (2006).
   Google Scholar
• Short review that covers the history of the metabolic syndrome and provides a succinct summary about the various clinical parameters used by different organizations to define metabolic syndrome.
   Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 265, 1415–1428 (2005).
   Google Scholar
• In this excellent review, the authors provide a comparison of definitions of the metabolic syndrome, worldwide prevalence of the syndrome, various metabolic parameters impacted by insulin resistance and management of metabolic risk factors.
   Google Scholar
• Gill H, Mungo M, Whaley-Connell A, Stump C, Sowers JR: The key role of insulin resistance in the cardiometabolic syndrome. Am. J. Med. Sci. 330, 290–294 (2005).
   Google Scholar
• Govindarajan G, Whaley-Connell A, Mungo M, Stump C, Sowers JR: The cardiometabolic syndrome as a cardiovascular risk factor. Am. J. Med. Sci. 330, 311–318 (2005).
   Google Scholar
• Hafidh S, Senkottaiyan N, Villarreal D, Alpert MA: Management of the metabolic syndrome. Am. J. Med. Sci. 330, 343–351, (2005).
   Google Scholar
• Miranda PJ, DeFronzo RA, Califf RM: Metabolic syndrome: definition, pathophysiology, and mechanisms. Am. Heart J. 149, 33–45 (2005).
   Google Scholar
• Provides more recent understanding about the criteria and definitions of metabolic syndrome, the metabolic components of the syndrome and the underlying mechanisms involved in its pathophysiology.
   Google Scholar
• Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56, 45–62 (2005).
   Google Scholar
• Useful update regarding the clinical and molecular aspects of the metabolic syndrome.
   Google Scholar
• Reaven GM: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 47, 201–210 (2005).
   Google Scholar
• Addresses insulin resistance with emphasis on a number of clinical conditions that are known to be associated with insulin resistance and compensatory hyperinsulinemia.
   Google Scholar
• Poole R, Byrne CD: The metabolic syndrome and type 2 diabetes. Minerva Endocrinol. 30, 139–159 (2005).
   Google Scholar
• Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J. Am. Coll. Cardiol. 47, 1093–1100 (2006).
   Google Scholar
• Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 33, 351–375 (2004).
   Google Scholar
• Ford ES, Giles WH, Mokdad AK: Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27, 2444–2449 (2004).
   Google Scholar
• Haffner S, Taegtmeyer H: Epidemic obesity and the metabolic syndrome. Circulation 108, 1541–1545 (2003).
   Google Scholar
• Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Survey. JAMA 287, 356–359 (2002).
   Google Scholar
• Alexender CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210–1214 (2003).
   Google Scholar
• Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH: Prevalence of a metabolic syndrome phenotype in aldolescents: findings from the third National Health and Nutrition Examination Survey, 1988– 1994. Arch. Pediatr. Adolesc. Med. 157, 821–827 (2003).
   Google Scholar
• Grundy SM: A constellation of complications: the metabolic syndrome. Clin. Cornerstone 7, 36–45 (2005).
   Google Scholar
• Ginsberg HN, Huang LS: The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J. Cardiovasc. Risk 7, 325–331 (2000).
   Google Scholar
• Adams LA, Angulo P, Lindor KD: Nonalcoholic fatty liver disease. CMAJ 172, 899–905 (2005).
   Google Scholar
• Important review describing an association between nonalcoholic fatty liver disease and the metabolic syndrome.
   Google Scholar
• Marchesini G, Babini M: Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardiol. 54, 229–239 (2006).
   Google Scholar
• Provides evidence in support of nonalcoholic fatty liver disease as being a component of the metabolic syndrome.
   Google Scholar
• McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of Type 2 diabetes. Diabetes 51, 7–18 (2002).
   Google Scholar
• Implicates dysregulated fatty-acid metabolism in the etiology of Type 2 diabetes.
   Google Scholar
• Goodpaster BH, Wolf D: Skeletal muscle lipid accumulation in obesity, insulin resistance, and Type 2 diabetes. Pediatric Diabetes 5, 219–226 (2004).
   Google Scholar
• Borradaile NM, Schaffer JE: Lipotoxicity in the heart. Curr. Hypertens. Res. 7, 412–417 (2005).
   Google Scholar
• Rhodes CJ: Type 2 diabetes—a matter of β-cell life and death? Science 307, 380–384 (2005).
   Google Scholar
• Stumvoll M, Goldstein B, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365, 1333–1346 (2005).
   Google Scholar
• Zhang R, Liao J, Morse S, Donelon S, Reisin E: Kidney disease and the metabolic syndrome. Am. J. Med. Sci. 330, 319–325 (2005).
   Google Scholar
• Rosmond R: Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 30, 1–10 (2005).
   Google Scholar
• Wang M: The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr. Metab. 2, 3–16 (2005).
   Google Scholar
• Unger RH: Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144, 5159–5165 (2003).
   Google Scholar
• Young LR, Nestle M: The contribution of expanding portion sizes to the US obesity epidemic. Am. J. Public Health 92, 246–249 (2002).
   Google Scholar
• Bray GA, Popkin BM: Dietary fat intake does affect obesity. Am. J. Clin. Nutr. 68, 1157–1173 (1998).
   Google Scholar
• Johnson RK, Frary C: Choose beverages and foods to moderate your intake of sugars: the 2000 dietary guidelines for Americans – what’s all the fuss about? J. Nutr. 131, S2766–S2771 (2001).
   Google Scholar
• Bray GA, Nielsen SJ, Popkin BM: Consumption of high-fructose corn syrup beverages may play a role in the epidemic of obesity. Am. J. Clin. Nutr. 79, 537–543 (2004).
   Google Scholar
• Evidence that overconsumption of calorically sweetened soft drinks may be an important contributor to the epidemic of obesity, in part through the large portion sizes of these beverages and through the increased intake of fructose from high-fructose corn syrup and sucrose.
   Google Scholar
• Stone NJ, Saxon D: Approach to treatment of the patient with metabolic syndrome: lifestyle therapy. Am. J. Cardiol. 96, E15–E21 (2005).
   Google Scholar
• Corella D, Ordovas JM: The metabolic syndrome: a crossroad for genotype–phenotype associations in atherosclerosis. Curr. Atheroscler. Rep. 6, 186–196 (2004).
   Google Scholar
• Roche HM, Phillips C, Gibney MJ: The metabolic syndrome: the crossroads of diet and genetics. Proc. Nutr. Soc. 64, 371–377 (2005).
   Google Scholar
• Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15, 2792–2800 (2004).
   Google Scholar
• Hutley L, Prins JB: Fat as an endocrine organ: relationship to the metabolic syndrome. Am. J. Med. Sci. 330, 280–289 (2005).
   Google Scholar
• Central theme of this review article is that adipose tissue not only functions as a lipid storage depot, but also plays a crucial role in the development of the metabolic syndrome and the progression of metabolic disease.
   Google Scholar
• Hitzenberger K, Richter-Quittner M: Ein Beitrag zum Stoffwechsel bei der vaskulären Hypertonie. Weiner Arch Innere Med. 2, 189–216 (1921).
   Google Scholar
• Hitzenberger K: Über den Blutdruck bei Diabetes Mellitus. Weiner Arch Innere Med. 2, 461–466 (1921).
   Google Scholar
• Kylin E: Hypertonie and Zuckerkrankheit. Zentralblatt für Innere Medizin 42, 873–877 (1921).
   Google Scholar
• Marañon G: Über Hypertonie and Zuckerkrankheit. Zentralblatt für Innere Medizin 43, 169–176 (1922).
   Google Scholar
• Kylin E: Studien über das Hypertoni- Hyperglycemi-Hyperurikmi syndrom. Zentralblatt für Innere Medizin 44, 105–112 (1923).
   Google Scholar
• Himsworth H: Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1, 127–130 (1936).
   Google Scholar
• Vague J: La differenciation sexuelle. Facteur determinant des formes de l’ obésite. Presse Méd. 55, 339–340 (1947).
   Google Scholar
• Vague J: The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am. J. Clin. Nutr. 4, 20–34 (1956).
   Google Scholar
• Albrink MJ, Meigs JW: Interrelationship between skinfold thickness, serum lipids and blood sugar in normal men. Am. J. Clin Nutr. 15, 255–261 (1964).
   Google Scholar
• Cámus JP: Goutte, diabète, hyperlipémie: un trisyndrome métabolique. Rev. Rhum. 33, 10–15 (1966).
   Google Scholar
• Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR: Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1, 1336–1337 (1966).
   Google Scholar
• Avogaro P, Crepaldi G: Plurimetabolic syndrome. Acta Diabetol. Lat. 4, 572–580 (1967).
   Google Scholar
• Mehnert H, Kuhlmann H: Hypertonie und diabetes mellitus. Dtsch Med. J. 19, 567–571 (1968).
   Google Scholar
• Hansfeld M, Leonhardt W: Das metabolische syndrom. Dt. Gesundh-Wesen 36, 545–551 (1981).
   Google Scholar
• Krotkiewski M, Björntorp P, Sjöström L, Smith U: Impact of obesity on metabolism in men and women: importance of regional adipose tissue distribution. J. Clin. Invest. 72, 1150–1162 (1983).
   Google Scholar
• Bjorntorp P: Metabolic implications of body fat distribution. Diabetes Care 14, 1132–1143 (1991).
   Google Scholar
• Kissebah AH, Vydelingum N, Murray R et al.: Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 54, 254–260 (1982).
   Google Scholar
• Modan M, Halkin H, Almog S et al.: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J. Clin. Invest. 75, 809–817 (1985).
   Google Scholar
• DeFronzo RA, Simonson D, Ferrannini E: Hepatic and peripheral insulin resistance: a common feature of Type 2 (non-insulindependent) and Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23, 313–319 (1982).
   Google Scholar
• Ferrannini E, Buzzigoli G, Bonadonna R et al.: Insulin resistance in essential hypertension. N. Engl J. Med. 317, 350–357 (1987).
   Google Scholar
• Wingard DL, Barret-Connor E, Criqui MH, Suarez L: Clustering of heart disease risk factors in diabetes compared to non-diabetic adults. Am. J. Epidemiol. 117, 19–26 (1983).
   Google Scholar
• Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37, 1595–1607 (1988).
   Google Scholar
• Classic paper in which Reaven introduced the concept that insulin resistance is central to the pathogenesis of Type 2 diabetes, hypertention, dyslipidemia and CAD.
   Google Scholar
• Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 149, 1514–1520 (1989).
   Google Scholar
• DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, 173–194 (1991).
   Google Scholar
• Zimmet PZ: Kelly West lecture 1991. Challenges in diabetes epidemiology – from west to the rest. Diabetes Care 15, 232–252 (1992).
   Google Scholar
• Hjermann I: The metabolic cardiovascular syndrome: syndrome X, Reaven’s syndrome, insulin resistance syndrome, atherothrombogenic syndrome. J. Cardiovasc. Pharmacol. 20(Suppl. 8), S5–S10 (1992).
   Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2005).
   Google Scholar
• Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34, 416–422 (1991).
   Google Scholar
• Reaven G: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol. Metab. Clin. North Am. 33, 283–303 (2004).
   Google Scholar
• Pouliot MC, Despres JP, Lemieux S et al.: Waist circumference and abdominal saggital diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol. 73, 460–468 (1994).
   Google Scholar
• Lemieux I, Pascot A, Couillard C et al.: Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia: hyperapolipoprotein B; small, dense LDL) in men? Circulation 102, 179–184 (2000).
   Google Scholar
• Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988– 1994. Arch. Intern. Med. 163, 427–436 (2003).
   Google Scholar
• Carr DB, Utzschneider KM, Hull RL et al.: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment III criteria for the metabolic syndrome. Diabetes 53, 2087–2094 (2004).
   Google Scholar
• Meigs JB, D’Agostina RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46, 1594–1600 (1997).
   Google Scholar
• Hanley AJ, Karter AJ, Festa A et al.: Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes 51, 2642–2647 (2002).
   Google Scholar
• Alberti KGMM, Zimmet P, Shaw J: The metabolic syndrome – a new worldwide definition. Lancet 366, 1059–1062 (2005).
   Google Scholar
• Reaven G: Insulin resistance, Type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation 112, 3030–3032 (2005).
   Google Scholar
• Gustat J, Srinivasan SR, Elkasabany A, Berenson GS: Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: the Bogalusa Heart Study. J. Clin. Epidemiol. 55, 997–1006 (2002).
   Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929–1935 (2004).
   Google Scholar
• Authors conclude that the metabolic syndrome and its components are common in women with polycystic ovary syndrome, placing them at a greater risk for cardiovascular disease.
   Google Scholar
• American Diabetes Association: Consensus Development Conference on Insulin Resistance. 5–6 November 1997. Diabetes Care 21, 310–314 (1998).
   Google Scholar
• Alberti KG, Zimmet PZ: Definition, diagnosis and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998).
   Google Scholar
• Definition, Diagnosis and Classification of Diabetes Mellitus and its complications. Geneva, Switzerland: Department of Noncommunible Disease Surveillance. World Health Organization (1999).
   Google Scholar
• Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Metab. 16, 442–443 (1999).
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).
   Google Scholar
• Einhorn D, Reaven GM, Cobin RH et al.: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237–252 (2003).
   Google Scholar
• Grundy S, Brewer HB, Cleeman J, Smith SC, Lenfant C: For the conference participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association on scientific issues related to definition. Circulation 109, 433–438 (2004).
   Google Scholar
• Gotto AM Jr, Blackburn GL, Dailey GE III et al.: The metabolic syndrome: a call to action. Coron. Artery Dis. 17, 77–80 (2006).
   Google Scholar
• Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649–688 (1999).
   Google Scholar
• Excellent review that discusses molecular and physiological aspects of peroxisome proliferator-activated receptors (PPARs).
   Google Scholar
• Lee C-H, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferatoractivated receptors. Endocrinology 144, 2201–2207 (2003).
   Google Scholar
• Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527–550 (2000).
   Google Scholar
• Describes the molecular characteristics and physiological function of PPARs and discusses the potential utility of PPARs as molecular targets for the development of drugs to treat human metabolic diseases.
   Google Scholar
• Berger J, Moller DE: The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409–435 (2002).
   Google Scholar
• Covers the molecular mechanisms of PPAR action and the involvement of PPARs in the etiology and treatment of several chronic diseases.
   Google Scholar
• Francis GA, Fayard E, Picard F, Auwerx J: Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65, 261–311 (2003).
   Google Scholar
• Broad description of nuclear receptors in relation to the control of the metabolic processes is presented.
   Google Scholar
• Ferré P: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53(Suppl. 1), S43–S50 (2004).
   Google Scholar
• Emphasizes PPARs role as a major regulator of lipid and glucose homeostasis.
   Google Scholar
• Tham DM, Wang Y-X, Rutledge JC: Modulation of vascular inflammation by PPARs. Drug News Perspect. 16, 109–116 (2003).
   Google Scholar
• Castrillo A, Tontonoz P: Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 20, 455–480 (2004).
   Google Scholar
• Comprehensive review of nuclear receptors literature with an emphasis on the roles of PPARs and liver X receptors (LXRs) in the regulation of macrophage lipid homeostasis, inflammation and gene expression, and their relevance to cardiovascular disease.
   Google Scholar
• Kosadinova R, Wahli W, Michalik L: PPARs in diseases: control mechanisms of inflammation. Curr. Med. Chem. 12, 2995–3009 (2005).
   Google Scholar
• Chen YE, Fu M, Zhang J et al.: Peroxisome proliferator-activated receptors and cardiovascular system. Vit. Horm. 66, 157–188 (2003).
   Google Scholar
• Marx N, Duez H, Fruchart J-C, Staels B: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94, 1168–1178 (2004).
   Google Scholar
• Li AC, Palinski W: Peroxisome proliferatoractivated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu. Rev. Pharmacol. Toxicol. 46, 1–39 (2006).
   Google Scholar
• Important review with primary emphasis on the roles of PPARs in macrophage biology, including macrophage/foam-cell formation.
   Google Scholar
• Lefebvre P, Chinetti G, Fruchart J-C, Staels B: Sorting out the roles of PPAR in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571–580 (2006).
   Google Scholar
• Semple RK, Chatterjee VK, O’Rahilly S: PPAR and human metabolic disease. J. Clin. Invest. 116, 581–589 (2006).
   Google Scholar
• Barish GD, Narkar VA, Evans RM: PPAR : a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116, 590–597 (2006).
   Google Scholar
• Provides evidence that PPAR´ may be a new therapeutic target that may achieve both triglyceride lowering as well as improving insulin sensitivity.
   Google Scholar
• Guan Y-F, Breyer MD: Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 60, 14–30 (2001).
   Google Scholar
• Mandard S, Müller M, Kersten S: Peroxisome proliferator-activated receptor target genes. Cell. Mol. Life Sci. 61, 393–416 (2004).
   Google Scholar
• Provides an extensive list of PPARα-regulated target genes.
   Google Scholar
• Reddy JK: Peroxisome proliferators and peroxisome proliferators-activated receptor . Biotic and xenobiotic sensing. Am. J. Pathol. 164, 2305–2321 (2004).
   Google Scholar
• Barbier O, Torra P, Duguay Y et al.: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22, 717–726 (2002).
   Google Scholar
• Hsu M-H, Palmer CAN, Song W, Griffin KJ, Johnson EF: A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J. Biol. Chem. 273, 27088–27997 (1998).
   Google Scholar
• Privalsky ML: The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu. Rev. Physiol. 66, 315–360 (2004).
   Google Scholar
• Most recent review on the corepressor-mediated, negative regulation of PPARs function.
   Google Scholar
• Chakravarthy MV, Pan Z, Zhu Y et al.: ‘New’ hepatic fat activates PPAR to maintain glucose, lipid and cholesterol homeostasis. Cell Metab. 1, 309–322 (2005).
   Google Scholar
• Spiegelman BM, Heinrich R: Biological control through regulated transcriptional coactivators. Cell 119, 157–167 (2004).
   Google Scholar
• Main focus of this article is on the coactivator regulation of nuclear hormone receptors.
   Google Scholar
• Bishop-Bailey D: Peroxisome proliferator-activated receptors in the cardiovascular system. Brit. J. Pharmacol. 129, 823–834 (2000).
   Google Scholar
• Akiyama TE, Meinke PT, Berger JP: PPAR ligands: potential therapies for metabolic syndrome. Curr. Diab. Rep. 5, 45–52 (2005).
   Google Scholar
• Kuwabara K, Murakami K, Todo M et al.: A novel selective peroxisome proliferatoractivated -agonist, 2-methyl-c-5-[4-[5- methyl-2-(4-methylphenyl)-4- oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. J. Pharmacol. Exp. Ther. 309, 970–977 (2004).
   Google Scholar
• Pelton PD, Patel M, Demarest KT: Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr. Top. Med. Chem. 5, 265–282 (2005).
   Google Scholar
• Staels B, Fruchart J-C: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54, 2460–2470 (2005).
   Google Scholar
• Useful, systematic review that provides clinical trial data about the PPAR agonists in the management of dyslipidemia and cardiovascular disease.
   Google Scholar
• Israelian-Konaraki Z, Reaven PD: Peroxisome proliferators-activated receptor- and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 103, 1–9 (2005).
   Google Scholar
• Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D: Role of PPAR- agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr. Drug Targets Cardiovasc. Haematol. Disord. 5, 377–386 (2005).
   Google Scholar
• Aasum E, Belke DD, Severson DL et al.: Cardiac function and metabolism in the Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR- activator. Am. J. Physiol. Heart Circ. Physiol. 283, H949–H957 (2002).
   Google Scholar
• Schäfer SA, Hansen BC, Völkl A, Fahimi HD, Pill J: Biochemical and morphological effects of K-111, a peroxisome proliferator-actvated receptor (PPAR) activator. Biochem. Pharmacol. 68, 239–251 (2004).
   Google Scholar
• Cheng PT, Mukherjee R: PPARs as targets for metabolic and cardiovascular diseases. Mini Rev. Med. Chem. 5, 741–753 (2005).
   Google Scholar
• Brandt JM, Djouadi F, Kelley DP: Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor . J. Biol. Chem. 273, 23786–23792 (1998).
   Google Scholar
• Mascaró C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D: Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferators-activated receptor. J. Biol. Chem. 273, 8560–8563 (1998).
   Google Scholar
• Barrero MJ, Camarero N, Marrero PF, Haro D: Control of human carnitine palmitoyltransferase II gene transcription by peroxisome-activated receptor through a partially conserved proliferator proliferator-responsive element. Biochem. J. 369, 721–729 (2003).
   Google Scholar
• Gulick T, Cresci S, Caira T, Moore DD, Kelly DP: The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc. Natl Acad. Sci. USA 91, 11012–11016 (1994).
   Google Scholar
• Rodriguez JC, Gil-Gomez G, Hegardt FG, Haro D: Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy- 3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269, 18767–18772 (1994).
   Google Scholar
• Lee SS-T, Pineau T, Drago J et al.: Targeted disruption of the isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15, 3012–3022 (1995).
   Google Scholar
• Zhang B, Marcus SL, Sajjadi FG et al.: Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal anoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc. Natl Acad. Sci. USA 89, 7541–7545 (1992).
   Google Scholar
• Nicolas-Frances V, Dasari VK, Abruzzi E, Osumi T, Latruffe N: The peroxisome proliferator response element (PPRE) present at positions -681/-669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally interacts differently with PPAR and HNF- . Biochem. Biophys. Res. Comunn. 269, 347–351 (2000).
   Google Scholar
• Aldridge TC, Tungwood JD, Green S: Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem. J. 306, 473–479 (1995).
   Google Scholar
• Peters JM, Hennuyer N, Staels B et al.: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor -deficient mice. J. Biol. Chem. 272, 27307–27312 (1997).
   Google Scholar
• Aoyama T, Peters JM, Iritani N et al.: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor (PPAR ). J. Biol. Chem. 273, 5678–5684 (1998).
   Google Scholar
• Costet P, Legerdre C, More J, Edger A, Galtier P, Pineau T: Peroxisome proliferator-activated receptor -isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273, 29577–29585 (1998).
   Google Scholar
• Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5’ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11, 433–439 (1992).
   Google Scholar
• Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W: Peroxisome proliferator-activated receptor mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489–1498 (1999).
   Google Scholar
• Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor (PPAR ) in the cellular fasting response: the PPAR -null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473–7478 (1999).
   Google Scholar
• Huss JM, Kelly DP: Nuclear receptor signaling and cardiac energetics. Circ. Res. 95, 568–578 (2004).
   Google Scholar
• Riby JE, Fujisawa T, Kretchmer N: Fructose absorption. Am. J. Clin. Nutr. 58, S748–S753 (1993).
   Google Scholar
• Aoyama Y, Yoshida A, Ashida K: Effect of dietary fats and fatty acids on the liver lipid accumulation induced by feeding a protein-repletion diet containing fructose to protein-depleted rats. J. Nutr. 104, 741–746 (1974).
   Google Scholar
• Jurgens H, Hass W, Castaneda TR et al.: Consuming fructose-sweetened beverages increases body adiposity in mice. Obes. Res. 13, 1146–1156 (2005).
   Google Scholar
• Nagai Y, Nishio Y, Nakamura T, Maegawa H, Kikkawa R, Kashiwagi A: Amelioration of high fructose-induced metabolic derangements by activation of PPAR . Am. J. Physiol. Endocrinol. Metab. 282, E1180–E1190 (2002).
   Google Scholar
• Kelley GL, Allan G, Azhar S: High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology 145, 548–555 (2004).
   Google Scholar
• Wei Y, Wang D, Pagliassotti MJ: Fructose selectively modulates c-jun N-terminal kinase activity and insulin signaling in rat primary hepatocytes. J. Nutr. 135, 1642–1646 (2005).
   Google Scholar
• Basciano H, Federico L, Adeli K: Fructose, insulin resistance, and metabolic dyslipidemia. Nutr. Metab. (Lond.). 2, 5 (2005).
   Google Scholar
• Berger PM, Kelly DP: PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10, 238–245 (2000).
   Google Scholar
• Djouadi F, Brandt J, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelley DP: The role of the peroxisome proliferator-activated receptor (PPAR ) in the control of cardiac lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids 60, 339–343 (1999).
   Google Scholar
• Watanabe K, Fujii H, Takahashi T et al.: Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor associated with age-dependent cardiac toxicity. J. Biol. Chem. 275, 22293–22299 (2000).
   Google Scholar
• Campbell FM, Kozak R, Wagner A et al.: A role for PPAR in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPAR are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J. Biol. Chem. 277, 4098–4103 (2002).
   Google Scholar
• Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferatoractivated receptor (PPAR ) in the cellular fasting response: the PPAR -null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473–7478 (1996).
   Google Scholar
• Finck BN, Lehman JJ, Leone TC et al.: The cardiac phenotype induced by PPAR overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109, 121–130 (2002).
   Google Scholar
• Finck BN, Han X, Courtois M et al.: A critical role for PPAR -mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl Acad. Sci. USA 100, 1226–1231 (2003).
   Google Scholar
• Park S-Y, Cho Y-R, Fink BN et al.: Cardiacspecific overexpression of peroxisome proliferator-activated receptor- causes insulin resistance in heart and liver. Diabetes 54, 2514–2524 (2005).
   Google Scholar
• Suggests that heart-specific overexpression of PPARα as it occurs in diabetic hearts, leads to cardiac insulin-resistance along with defects in insulin signaling and STAT5 activity and reduced cardiac function.
   Google Scholar
• Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP: Deactivation of peroxisome proliferator-activated receptor- during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723–1730 (2000).
   Google Scholar
• Young ME, Laws FA, Goodwin GW, Taegtmeyer H: Reactivation of peroxisome proliferator-activated receptor is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. 276, 44390–44395 (2001).
   Google Scholar
• Huss JM, Levy FH, Kelly DP: Hypoxia inhibits the PPAR /RXR gene regulatory pathway in cardiac myocytes. J. Biol. Chem. 276, 44390–44395 (2001).
   Google Scholar
• Razeghi P, Young ME, Abbasi S, Taegtmeyer H: Hypoxia in vivo decreases peroxisome proliferator-activated receptor -regulated gene expression in rat heart. Biochem. Biophys. Res. Commun. 287, 5–10 (2001).
   Google Scholar
• Kelley DP: PPARs of the heart: there is a crowd. Circ. Res. 92, 482–484 (2003).
   Google Scholar
• Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N: Expression of putative fatty acid transport genes are regulated by peroxisome proliferatoractivated receptor and activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273, 16710–16714 (1998).
   Google Scholar
• van der Vliet HN, Schaap FG, Levels JH et al.: Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun. 295, 1156–1159 (2002).
   Google Scholar
• Schultze A, Alborn WE, Mewton RK, Konrad RJ: Administration of PPAR agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. J. Lipid Res. 46, 1591–1595 (2005).
   Google Scholar
• Demonstrates that PPARα agonist exerts its hypotriglyceridemic effect by modulating levels of apolipoprotein (Apo)A-V and ApoA-V/ApoC-III (lipoprotein lipase inhibitor).
   Google Scholar
• Prieur X, Schapp FG, Coste H, Rodríguez JC: Hepatocyte nuclear factor-4 regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by peroxisome proliferatoractivated receptor- coactivator-1a, AMPactivated protein kinase, and mitogenactivated protein kinase pathway. Mol. Endocrinol. 19, 3107–3125 (2005).
   Google Scholar
• Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodríguez JC: Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J. Biol. Chem. 260, 27533–27543 (2005).
   Google Scholar
• Dobbins RL, Chester MW, Stevenson BE, Daniels MB, Stein DT, McGarry JD: A fatty acid-dependent step is critically important for both glucose- and non-glucosestimulated insulin secretion. J. Clin. Invest. 101, 2370–2376 (1998).
   Google Scholar
• Wollheim CB, Maechler P: -cell mitochondria and insulin secretion: messenger role of nucleotides and metabolites. Diabetes 51(Suppl. 1), S37–S42 (2002).
   Google Scholar
• Yaney GC, Corkey BE: Fatty acid metabolism and insulin secretion in pancreatic cells. Diabetologia 46, 1297–1312 (2003).
   Google Scholar
• Sugden MC, Holmes MJ: Potential role of peroxisome proliferator-activated receptor- in the modulation of glucose-stimulated insulin secretion. Diabetes 53(Suppl. 1), S71–S81 (2004).
   Google Scholar
• Zhou Y-T, Shimabukuro M, Wang M-Y et al.: Role of peroxisome proliferatoractivated receptor in disease of pancreatic -cells. Proc. Natl Acad. Sci. USA 95, 8898–8903 (1998).
   Google Scholar
• Roduit R, Morin J, Massé F et al.: Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-1 gene in the pancreatic -cell. J. Biol. Chem. 275, 35799–35806 (2000).
   Google Scholar
• Suggests that hyperglycemia downregulates PPARα gene expression in pancreatic β-cells.
   Google Scholar
• Gremlich S, Nolan C, Roduit R et al.: Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor transcription up-regulation of fatty acid oxidation. Endocrinology 146, 375–382 (2005).
   Google Scholar
• Ravnskjaer K, Boergesen M, Rubi B et al.: Peroxisome proliferator-activated receptor (PPAR ) potentiates, whereas PPAR attenuates, glucose-stimulated insulin secretion in pancreatic -cells. Endocrinology 146, 3266–3276 (2005).
   Google Scholar
• Guerre-Millo M, Gervois P, Raspe E et al.: Peroxisome proliferator-activated receptor activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638–16642 (2000).
   Google Scholar
• Sugden MC, Bulmer K, Gibbons GF, Knight BL, Holness MJ: Peroxiosmeproliferator- activated receptor- (PPAR ) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochem. J. 364, 361–368 (2002).
   Google Scholar
• Ye J-M, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW: Peroxisome proliferator-activated receptor (PPAR) activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR activation. Diabetes 50, 411–417 (2001).
   Google Scholar
• Chou CJ, Haluzik M, Gregory C et al.: WY14,643, a peroxisome proliferatoractivated receptor (PPAR ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatropic A-ZIP/F-1 mice. J. Biol. Chem. 277, 24484–24489 (2002).
   Google Scholar
• Experimental evidence is presented to suggest that administration of PPARα agonist improves hepatic and muscle steatosis and causes a reversal of insulin resistance in lipoatropic A-ZIP/F-1 mice.
   Google Scholar
• Koh EH, Kim MS, Park JY et al.: Peroxisome proliferator-activated receptor (PPAR)- activation prevents diabetes in OLETF rats: comparison with PPAR- activation. Diabetes 52, 2331–2337 (2003).
   Google Scholar
• Guan Y: Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 15, 2801–2815 (2004).
   Google Scholar
• Li AC, Binder C, Gutierrez A et al.: Differential inhibition of macrophage foamcell formation and atherosclerosis in mice by PPAR , β/δ , and . J. Clin. Invest. 114, 1564–1576 (2004).
   Google Scholar
• Provides evidence that administration of PPARα agonists to male lwo-density lipoprotein receptor-deficient mice markedly attenuates atherosclerosis. This treatment also inhibits macrophage foam-cell formation.
   Google Scholar
• Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL: Peroxisome proliferator-activated receptor- selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol. Cell. Biochem. 285, 35–50 (2006).
   Google Scholar
• Sugden MC, Greenwood GK, Smith ND, Holness MJ: Peroxisome proliferator-activated receptor- activation during pregnancy attenuates glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, without impairing pregnancy-induced increases in -cell glucose sensing and responsiveness. Endocrinology 144, 146–153 (2003).
   Google Scholar
• Plutzky J: The potential role of peroxisome proliferator-activated receptors on inflammation in Type 2 diabetes mellitus and atherosclerosis. Am. J. Cardiol. 92, 34–41 (2003).
   Google Scholar
• Bloomgarden ZT: Inflammation, atherosclerosis, and aspects of insulin action. Diabetes Care 28, 2312–2319 (2005).
   Google Scholar
• Lusis AJ: Atherosclerosis. Nature 407, 233–241 (2000).
   Google Scholar
• Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685–1695 (2005).
   Google Scholar
• Beaven SW, Tontonoz P: Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 57, 313–329 (2006).
   Google Scholar
• Blaschke F, Takata Y, Caglayan E et al.: Obesity, peroxisome proliferator activated receptor, and atherosclerosis in Type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26, 28–40 (2005).
   Google Scholar
• Skalen K, Gustafsson M, Rydberg EK et al.: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417, 750–754 (2002).
   Google Scholar
• Inoue I, Shino K, Awata T, Katayama S: Expression of peroxisome proliferatoractivated receptor (PPAR ) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246, 370–374 (1998).
   Google Scholar
• Staels B, Koening W, Habib A, Merval R, Lebret M, Torra IP: Activation of human aortic smooth-muscle cells is inhibited by PPAR but not by PPAR activators. Nature 393, 790–793 (1998).
   Google Scholar
• Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z: Activation of proliferator-activated receptor and induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273, 25573–25580 (1998).
   Google Scholar
• Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P: CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferatoractivated receptors. Circulation 101, 2411–2417 (2000).
   Google Scholar
• Zhu L, Bisgaier CL, Aviram M, Newton RS: 9-Cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. Arterioscler. Thromb. Vasc. Biol. 19, 2105–2111 (1999).
   Google Scholar
• Delerive P, Martin-Nizard F, Chinetti G et al.: Peroxisome proliferator-activated receptor activators inhibit thrombininduced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85, 394–402 (1999).
   Google Scholar
• Jackson SM, Parhami F, Xi XP et al.: Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19, 2094–2104 (1999).
   Google Scholar
• Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99, 3125–3131 (1999).
   Google Scholar
• Shu H, Wong B, Zhou G et al.: Activation of PPAR or reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. 267, 345–349 (2000).
   Google Scholar
• Chinetti G, Lestavel S, Bocher V et al.: PPAR- and PPAR- activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7, 53–58 (2001).
   Google Scholar
• Neve BP, Corseaux D, Chinetti G et al.: PPAR agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103, 207–212 (2001).
   Google Scholar
• Marx N, Mackman N, Schonbeck U et al.: PPAR activators inhibit tissue factor expression and activity in human monocytes. Circulation 103, 213–219 (2001).
   Google Scholar
• Delerive P, De Bosscher K, Vanden-Berghe W, Fruchart JC, Haegeman G, Staels B: DNA binding-independent induction of I B gene transcription by PPAR . Mol. Endocrinol. 16, 1029–1039 (2002).
   Google Scholar
• Delerive P, De Bosscher K, Besnard S, Vanden-Berghe W, Peters JM, Gonzalez FJ: Peroxisome proliferator-activated receptor negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF- B and AP-1. J. Biol. Chem. 274, 32048–32054 (1999).
   Google Scholar
• Poynter ME, Daynes RA: Peroxisome proliferator-activated receptor activation modulates cellular redox status, represses nuclear factor- B signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273, 32833–32841 (1998).
   Google Scholar
• Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B: Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIB. Int. J. Clin. Pharmacol. Ther. 36, 345–349 (1998).
   Google Scholar
• Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S: Peroxisome proliferator-activated receptor agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24, 658–663 (2004).
   Google Scholar
• Loscalzo J: Nitric oxide and vascular tone. N. Engl. J. Med. 333, 251–253 (1995).
   Google Scholar
• De Caterina R, Libby P, Peng HB et al.: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96, 60–68 (1995).
   Google Scholar
• Li AC, Glass CG: PPAR- and LXRdependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45, 2161–2173 (2004).
   Google Scholar
• Devchand PR, Keller H, Peters JM, Vasquez M, Gonzalez FJ, Wahli W: The PPAR - leukotriene B4 pathway to inflammation. Nature 384, 23–24 (1996).
   Google Scholar
• Provides evidence that leukotriene B4 is an activating ligand of PPARα and proposes a feedback mechanism between the duration of the inflammatory response and hepatic clearance of leukotriene B4 via PPAR α-controlled mechanisms.
   Google Scholar
• Cuzzocrea S, Mazzon E, Di Paola R et al.: The role of the peroxisome proliferatorsactivated receptor- (PPAR- ) in the regulation of acute inflammation. J. Leukoc. Biol. 79, 999–1010 (2006).
   Google Scholar
• Tordjman K, Bernal-Mizrachi C, Zemany L et al.: PPAR deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107, 1025–1034 (2001).
   Google Scholar
• Suggests that PPARα may contribute to the pathogenesis of diet-induced insulin resistance and atherosclerosis.
   Google Scholar
• Fu T, Kashireddy P, Borensztajn J: The peroxisome proliferator-activated receptor agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J. 373, 941–947 (2003).
   Google Scholar
• Demonstrates the hypercholesterolemic and proatherogenic actions of the PPAR agonist ciprofibrate in a mouse model of atherosclerosis.
   Google Scholar
• Claudel T, Leibowitz MD, Fievet C et al.: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl Acad. Sci. USA 98, 2610–2615 (2001).
   Google Scholar
• Duez H, Chao YS, Hernandez G et al.: Reduction of atherosclerosis by the peroxisome proliferator-activated receptor agonist fenofibrate in mice. J. Biol. Chem. 277, 48051–48057 (2002).
   Google Scholar
• Provides evidence that the PPAR agonist fenofibrate is highly effective in reducing atherosclerotic plaques in animal models of atherosclerosis.
   Google Scholar